Evidence map›Paper›PMID 33031315›Full record

Observational studyMedicine2020

Differences in human immunodeficiency virus-1C viral load and drug resistance mutation between plasma and cerebrospinal fluid in patients with human immunodeficiency virus-associated cryptococcal meningitis in Botswana.

Nametso Kelentse, Sikhulile Moyo, Mompati Mogwele, Kwana Lechiile, Natasha O Moraka, Dorcas Maruapula, Kaelo K Seatla, Lerato Esele, Kesaobaka Molebatsi, Tshepo B Leeme and 6 more

Open access · goldAbstract readComparative StudyObservational Study
In one paragraph

Observational study in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 4 countries.

Nametso KelentseBotswana Harvard AIDS Institute Partnership.ORCID 0000-0003-2433-2416
Sikhulile MoyoBotswana Harvard AIDS Institute Partnership.
Mompati MogweleBotswana Harvard AIDS Institute Partnership.
Kwana LechiileBotswana Harvard AIDS Institute Partnership.
Natasha O MorakaBotswana Harvard AIDS Institute Partnership.
Dorcas MaruapulaBotswana Harvard AIDS Institute Partnership.
Kaelo K SeatlaBotswana Harvard AIDS Institute Partnership.
Lerato EseleBotswana Harvard AIDS Institute Partnership.
Kesaobaka MolebatsiBotswana Harvard AIDS Institute Partnership.
Tshepo B LeemeBotswana Harvard AIDS Institute Partnership.
David S LawrenceBotswana Harvard AIDS Institute Partnership.
Rosemary MusondaBotswana Harvard AIDS Institute Partnership.
Ishmael KasvosveUniversity of Botswana, Department of Medical Laboratory Sciences, Gaborone, Botswana.
Thomas S HarrisonCentre for Global Health, Institute for Infection and Immunity, St. George's University of London, United Kingdom.
Joseph N JarvisBotswana Harvard AIDS Institute Partnership.
Simani GaseitsiweBotswana Harvard AIDS Institute Partnership.
Botswana Harvard AIDS Institute Partnership · BWUniversity of Botswana · BWHarvard University · USIndividual Differences · USLondon School of Hygiene & Tropical Medicine · GBSt George's, University of London · GB

Funding

Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ROBERT GROSS · 1999 to 2026
$78.6M
Training in HIV Genomics, Treatment, and Cure Research in BotswanaD43TW009610 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI SHAHIN LOCKMAN, Joseph Moeketsi Makhema · 2013 to 2026
$4.4M
Department of Health RP-2017-08-ST2-012Medical Research Council MC_PC_MR/P006922/1Wellcome Trust
6 · The paper itself

Abstract

To determine effects of cryptococcal meningitis (CM) on human immunodeficiency virus (HIV)-1C cerebrospinal fluid (CSF) viral escape, CSF/plasma viral discordance, and drug resistance mutation (DRM) discordance between CSF and plasma compartments, we compared CSF and plasma viral load (VL) and DRMs in individuals with HIV-associated CM in Botswana.This cross-sectional study utilized 45 paired CSF/plasma samples from participants in a CM treatment trial (2014-2016). HIV-1 VL was determined and HIV-1 protease and reverse transcriptase genotyping performed. DRMs were determined using the Stanford HIV database. CSF viral escape was defined as HIV-1 ribonucleic acid ≥0.5 log10 higher in CSF than plasma and VL discordance as CSF VL > plasma VL.HIV-1 VL was successfully measured in 39/45 pairs, with insufficient sample volume in 6; 34/39 (87.2%) participants had detectable HIV-1 in plasma and CSF, median 5.1 (interquartile range: 4.7-5.7) and 4.6 (interquartile range:3.7-4.9) log10 copies/mL, respectively (P≤.001). CSF viral escape was present in 1/34 (2.9%) and VL discordance in 6/34 (17.6%). Discordance was not associated with CD4 count, antiretroviral status, fungal burden, CSF lymphocyte percentage nor mental status. Twenty-six of 45 (57.8%) CSF/plasma pairs were successfully sequenced. HIV-1 DRM discordance was found in 3/26 (11.5%); 1 had I84IT and another had M46MI in CSF only. The third had K101E in plasma and V106 M in CSF.Our findings suggest that HIV-1 escape and DRM discordance may occur at lower rates in participants with advanced HIV-disease and CM compared to those with HIV associated neurocognitive impairment.

Indexed as

AdultCross-Sectional StudiesDrug Resistance, ViralFemaleGenes, polHIV-1HIV InfectionsHumansMaleMeningitis, CryptococcalMutationRetrospective StudiesViral Load

Identifiers

PMID33031315
PMCPMC7544309
OpenAlexW3091975443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.